Lataa...

From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma

Multiple myeloma is characterized by periods of remission followed by relapse, and eventually the disease becomes refractory to treatment. While patients with multiple myeloma frequently receive multiple lines of treatment, antimyeloma agents are associated with a number of toxicities that can impac...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijä: Siegel, David S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2013
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3854560/
https://ncbi.nlm.nih.gov/pubmed/24319571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620713511176
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!